AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01576692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy \& Procedure Manual.
Study NCT01576692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT00754910 — intervention group
Intervention type: DRUG
Intervention: porfimer sodium
Description: Given IV
Study NCT00754910 — intervention group
Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: Patients undergo bronchoscopy
Study NCT04743947 — intervention group
Intervention type: OTHER
Intervention: No intervention; observational study
Description: no intervention
Study NCT03602079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
Study NCT00091715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
Study NCT00091715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 6 months followed by an open-label period
Study NCT02096341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly
Study NCT01216436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with RNA-transfected mature autologous DC
Description: Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
Study NCT01028807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early feeding
Description: after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
Study NCT01028807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 day fasting
Description: Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
Study NCT01179958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 24 weeks of aerobic training, 4X/week
Study NCT01179958 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: stretching/toning
Description: stretches and toning exercises designed to promote flexibility and improved core strength
Study NCT04668859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
Study NCT04668859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylcellulose
Description: Placebo will consist of inert methylcellulose
Study NCT03021642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib test (Treatment Period 1)
Description: Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 1 (Day 1)
Study NCT03021642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib reference (Treatment Period 2)
Description: Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 2 (Day 22)
Study NCT03021642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib reference (Treatment Period 1)
Description: Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 1 (Day 1)
Study NCT03021642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib test (Treatment Period 2)
Description: Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 2 (Day 22)
Study NCT03025958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.
Study NCT03025958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Briefly, the dose prescribed was 70.4 Gy, 70.4 Gy, 60.8 Gy, and 54.4 Gy in 32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV)nx+rn, PTVnd, PTV1, and PTV2, respectively, using the simultaneous integrated boost technique.
Study NCT02916940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprophos
Description: Single subcutaneous injection of Diprophos, in the acute phase.
Study NCT01949363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
Study NCT06293612 — intervention group
Intervention type: OTHER
Intervention: No intervention was administrated to the two cohorts.
Study NCT01902290 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT01902290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Brodalumab administered subcutaneously
Study NCT00246428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Experimental manipulations will be evaluated 6, 9, and 12 months
Study NCT03042715 — intervention group
Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews
Description: phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
Study NCT02161211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De-coupling
Description: Six sessions of CBT for anxiety-alcohol de-coupling
Study NCT02161211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Reduction
Description: Six sessions of CBT for anxiety reduction.
Study NCT02161211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined
Description: Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
Study NCT02865382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: white light was used for colonoscopy withdrawal
Study NCT02865382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OE mode was used for colonoscopy withdrawal
Study NCT02948803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone based intervention with Active Coach app
Study NCT01312935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMX-60056
Description: investigational drug
Study NCT02776800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allevyn Life
Study NCT02776800 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foam dressing with an integrated adhesive border
Description: Foam dressing normally used by the home health agency
Study NCT03926221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Description: PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
Study NCT02497859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Egg Breakfast (EB)
Description: The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
Study NCT02497859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Breakfast (CB)
Description: The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
Study NCT02497859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
Study NCT02497859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
Study NCT02497859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Diet
Description: Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
Study NCT02497859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Diet
Description: Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
Study NCT00953758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
Study NCT01698346 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis vaccine
Description: Vaccination during pregnancy with a pertussis containing vaccine
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational handouts about to physical activity
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational handouts about to physical activity
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Access limited version of device app/website
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Access full version of interactive reward-based device app/website
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03223753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear physical activity tracking device
Study NCT00685126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl Inhalation Solution
Description: Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
Study NCT03223753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear physical activity tracking device
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00685126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl Inhalation Solution
Description: Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
Study NCT00685126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HCl Inhalation Solution
Description: Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
Study NCT01329393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits Management
Description: Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
Study NCT01329393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Illness Management and Recovery
Description: Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
Study NCT02733770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: Doppler ultrasound.
Study NCT02733770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic mini gastric bypass
Description: Doppler ultrasound.
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03223753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04336995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: contrast echocardiography
Description: giving echocardiographic contrast and taking echocardiographic images before and after exercise
Study NCT01188083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose Drink
Description: Fructose Based beverage 8 oz
Study NCT01188083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose Drink
Description: Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
Study NCT01662583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Study NCT01662583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written reminder
Study NCT01662583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Written reminder
Study NCT02789865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem, Levofloxacin and Metronidazole
Description: The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
Study NCT02789865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde appendicitis therapy (ERAT)
Description: The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
Study NCT02171754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBW 2992
Study NCT02171754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT02171754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02789865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: The patients will receive laparoscopic appendectomy according to standard routines.
Study NCT01052584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine- P. vivax
Description: Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
Study NCT01052584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine: P. vivax
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
Study NCT01052584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine: P. falciparum
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
Study NCT01839864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
Description: Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
Study NCT02926950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet. Route of administration: oral.
Study NCT02926950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet. Route of administration: oral.
Study NCT02926950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet. Route of administration: oral.
Study NCT02926950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet. Route of administration: oral.
Study NCT01387893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Digital Repetitive Infrapubic Pressure maneuver
Description: The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
Study NCT00993031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: LPV 200mg/r 50mg
Study NCT00993031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg
Study NCT00993031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine 300 mg
Study NCT00993031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Zidovudine 300 mg
Study NCT00993031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 150 mg
Study NCT00993031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 150 mg
Study NCT01568593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2750
Description: 1 drop in each eye 3 to 6 times daily during 84 days
Study NCT01568593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed
Description: 1 drop in each eye 3 to 6 times daily during 84 days
Study NCT04534660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMI-01
Description: SMI-01 is a device consisting of silk particles in a hydrogel carrier.
Study NCT00868283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: 30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.